About Us
|
contact Us
|
Sitemap
Call us: +1-855-455-8662
|
Home
Business Solutions
Business Research Reports
Business Consulting
On-site Implementation & Training Programs
Industry Trackers
Subscription Solutions
Industry Reports
News
Press
Login
Register
Home
Drugs by Therapeutic Area
Myasthenia Gravis Treatment Market Expected to Grow at 4.6% by 2032
Myasthenia Gravis Treatment Market By Treatment Type (Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy, Others), By End-Use (Hospitals, Clinics, Others) - Growth, Share, Opportunities & Competitive Analysis, 2024 - 2032
02 Nov 2023
Format
Request Sample
Report Summary
Table of contents
list of tables
list of figures
1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Myasthenia Gravis Treatment Market
2.2. Global Myasthenia Gravis Treatment Market, By Treatment Type, 2023 (US$ Million)
2.3. Global Myasthenia Gravis Treatment Market, By End-Use, 2023 (US$ Million)
2.4. Global Myasthenia Gravis Treatment Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023
3. Myasthenia Gravis Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Myasthenia Gravis Treatment Market Vendors
3.2. Strategies Adopted by Myasthenia Gravis Treatment Market Vendors
3.3. Key Industry Strategies
4. Myasthenia Gravis Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Myasthenia Gravis Treatment Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape
5. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Cholinesterase Inhibitors
5.3.2. Chronic Immunomodulators
5.3.3. Monoclonal Antibodies
5.3.4. Rapid Immunotherapies
5.3.5. Thymectomy
5.3.6. Others
6. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Others
7. North America Myasthenia Gravis Treatment Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
7.3. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
7.4.Myasthenia Gravis Treatment Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
7.4.1.1.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
7.4.1.2.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
7.4.1.3.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
8. UK and European Union Myasthenia Gravis Treatment Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
8.3. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
8.4.Myasthenia Gravis Treatment Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
8.4.1.1.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
8.4.1.2.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
8.4.1.3.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
8.4.1.4.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
8.4.1.5.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
8.4.1.6.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
9. Asia Pacific Myasthenia Gravis Treatment Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
9.3. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
9.4.Myasthenia Gravis Treatment Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
9.4.1.1.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
9.4.1.2.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
9.4.1.3.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
9.4.1.4.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
9.4.1.5.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
9.4.1.6.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
10. Latin America Myasthenia Gravis Treatment Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
10.3. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
10.4.Myasthenia Gravis Treatment Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
10.4.1.1.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
10.4.1.2.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
10.4.1.3.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
11. Middle East and Africa Myasthenia Gravis Treatment Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
11.3. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
11.4.Myasthenia Gravis Treatment Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
11.4.1.1.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
11.4.1.2.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2022-2032, USD (Million)
11.4.1.3.2. Myasthenia Gravis Treatment Market: By End-Use, 2022-2032, USD (Million)
12. Company Profile
12.1. Alexion Pharmaceutical Inc.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Grifols SA
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Avadel Pharmaceuticals plc.
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Novartis AG
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Pfizer, Inc.
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. AbbVie Inc.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. F. Hoffmann-La Roche Ltd.
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. GlaxoSmithKline plc
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Bausch Health Companies Inc.
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Shire plc
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Other Notable Players
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
Choose Licence Type
Single User Licence
$4500
Multi User license
$6500
Corporate license
$9000
Buy Now
Quick Contact
+1-855-455-8662
+91 77559-81103
sales@acutemarketreports.com
View Other Reports
Automotive
986
Chemicals and Materials
684
Consumer Goods
184
Energy
124
Food & Beverages
321
Medical Devices
178
Pharmaceutical & Healthcare
78
Technology
234